Anti-CD33 CAR T-cells 비교 | 바이오정보모아

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

Overview Toxicology Clinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	CGTStandard DatabasestalePhase 1 Anti-CD33 CAR T-cells (Anti-CD33 CAR T-cells) iCell Gene Therapeutics·CD33 12 trials

Overview Program	Anti-CD33 CAR T-cells
Overview Company	iCell Gene Therapeutics
Overview Modality	CGT
Overview Target	CD33
Overview Indication	Relapsed and/or Refractory Acute Myeloid Leukemia; High Risk Hematologic Malignancies
Overview Phase	PHASE_1
Overview Status	ACTIVE
Overview Content status	Standard Database
Overview Data Confidence	Data Confidence · Medium
Overview Development Signal	Development Signal · Watch
Overview Approval status	Investigational

Toxicology Major finding	A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.. VCAR33, a donor-derived CD33-directed chimeric antigen receptor T-cell (CAR T) product, was developed to decrease relapse of high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after allogeneic hematopoietic cell transplantation (alloHCT). We describe pre…
Toxicology CRS	Reported

Clinical Safety signal	A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.. VCAR33, a donor-derived CD33-directed chimeric antigen receptor T-cell (CAR T) product, was developed to decrease relapse of high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after allogeneic hematopoietic cell transplantation (alloHCT). We describe pre…
Clinical Program phase	PHASE_1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

Overview Toxicology Clinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	CGTStandard DatabasestalePhase 1 Anti-CD33 CAR T-cells (Anti-CD33 CAR T-cells) iCell Gene Therapeutics·CD33 12 trials

Overview Program	Anti-CD33 CAR T-cells
Overview Company	iCell Gene Therapeutics
Overview Modality	CGT
Overview Target	CD33
Overview Indication	Relapsed and/or Refractory Acute Myeloid Leukemia; High Risk Hematologic Malignancies
Overview Phase	PHASE_1
Overview Status	ACTIVE
Overview Content status	Standard Database
Overview Data Confidence	Data Confidence · Medium
Overview Development Signal	Development Signal · Watch
Overview Approval status	Investigational

Toxicology Major finding	A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.. VCAR33, a donor-derived CD33-directed chimeric antigen receptor T-cell (CAR T) product, was developed to decrease relapse of high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after allogeneic hematopoietic cell transplantation (alloHCT). We describe pre…
Toxicology CRS	Reported

Clinical Safety signal	A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.. VCAR33, a donor-derived CD33-directed chimeric antigen receptor T-cell (CAR T) product, was developed to decrease relapse of high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after allogeneic hematopoietic cell transplantation (alloHCT). We describe pre…
Clinical Program phase	PHASE_1